Published in Expert Opin Investig Drugs on December 01, 2001
Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut (2003) 1.67
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett (2007) 1.31
Protein prenyltransferases. Genome Biol (2003) 1.11
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood (2010) 0.93
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood (2011) 0.87
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica (2013) 0.79
Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J Med Chem (2010) 0.77
RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol (2001) 1.99
On two alternative mechanisms of ethane activation over ZSM-5 zeolite modified by Zn2+ and Ga1+ cations. Phys Chem Chem Phys (2005) 0.78